Akebia Therapeutics (AKBA) Enterprise Value (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Enterprise Value data on file, last reported at -$162.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 43.39% year-over-year to -$162.6 million in Q1 2026; TTM through Mar 2026 was -$162.6 million, a 43.39% decrease from a year earlier, with the FY2025 full-year figure at -$184.8 million, down 256.36% from the prior year.
• Enterprise Value for Q1 2026 stood at -$162.6 million, up from -$184.8 million in the prior quarter.
• Over the last five years, Enterprise Value for AKBA reached as high as -$34.0 million in Q3 2024 and fell as low as -$184.8 million in Q4 2025.
• Historically, Enterprise Value has averaged -$99.2 million across 5 years, with a median of -$90.5 million in 2022.
• Across the five-year window, Enterprise Value soared 67.86% in 2023 and sank 389.54% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$90.5 million in 2022, then soared by 52.55% to -$42.9 million in 2023, then declined by 20.84% to -$51.9 million in 2024, then slumped by 256.36% to -$184.8 million in 2025, then rose by 12.03% to -$162.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$162.6 million in Q1 2026, -$184.8 million in Q4 2025, and -$166.4 million in Q3 2025.